Whitepaper: Targeting kinases in the innate immune response
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
Tips and tricks for fully leveraging Advanced Flow Cytometry.
3 January 2024 | By Eurofins DiscoverX
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Register to access the very latest research, insights and innovations including CRISPR activation screening, AI-aided screening and using nanofibrillar cellulose hydrogels.
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
20 October 2023 | By Eurofins Discovery
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.